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Summary The neuropeptide oxytocin has a popular reputation of being the ‘love’ hormone.
Here we test meta-analytically whether experiments with intranasal administration of oxytocin
provide support for the proposed effects of oxytocin. Three psychological effects were subjected
to meta-analysis: facial emotion recognition (13 effect sizes, N = 408), in-group trust (8 effect
sizes, N = 317), and out-group trust (10 effect sizes; N = 505). We found that intranasal oxytocin
administration enhances the recognition of facial expressions of emotions, and that it elevates
the level of in-group trust. The hypothesis that out-group trust is significantly decreased in the
oxytocin condition was not supported. It is concluded that a sniff of oxytocin can change emotion
perception and behavior in trusting relationships.
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Open access under the Elsevier OA license.The neuropeptide oxytocin has a strong popular and scientific
reputation as the ‘love’ hormone that creates warm feelings
for offspring (Carter, 1998; Feldman et al., 2007, 2010;
Galbally et al., 2011; Insel, 1992, 2010) and supports
empathic concern for conspecifics (MacDonald and MacDo-
nald, 2010) through better recognition of emotional facial
expression (Bartz et al., 2010; Hurlemann et al., 2010; Kirsch
et al., 2005; Marsh et al., 2010). Moreover, it would elevate
the level of trust in other human beings (De Dreu et al., 2010;
Kosfeld et al., 2005). Experimental studies on oxytocin have
contributed to our knowledge of its associations with human* Corresponding author at: Centre for Child and Family Studies,
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Open access under the Elsevier OA license.perception and behavior. Here we test meta-analytically
whether experiments with intranasal administration of oxy-
tocin indeed confirm the proposed effects of oxytocin.
Whereas early behavioral experiments with intravenous
administration of oxytocin were short-lived due to disap-
pointing results (e.g., Bruins et al., 1992), in recent years the
number of experiments using intranasal administration of
oxytocin to study human perception, emotion, and behavior
has increased dramatically. The reason is that intranasal
administration indeed seems to induce replicable changes
in brain functioning (Perry et al., 2010; Riem et al., 2011),
perception (Theodoridou et al., 2009), and behavior (Naber
et al., 2010), in contrast to intravenously administered
oxytocin for which the blood—brain barrier might have been
difficult to pass. Nevertheless, salivary oxytocin might not be
an adequate indicator of levels of oxytocin in the brain, and
experimental effects of intranasally administered oxytocin
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tration. Double blind experiments are crucial to counteract
these potential biases (Eisenegger et al., 2010).
In oxytocin experiments two areas of human functioning
have been investigated most intensively: recognition of
facial expression of emotions such as fear, anger, happiness;
and feelings of trust in other human beings. Recently trust of
members of the in-group and out-group has been differen-
tiated (De Dreu et al., 2010). From an evolutionary perspec-
tive it is suggested that oxytocin may enhance the inclination
to protect offspring against predators (Carter, 1998), and
thus increase (defensive) aggression against threats from
out-group members.
Here we take stock of the first wave of experiments with
intranasal oxytocin administration, and test whether intra-
nasally administered oxytocin leads to better recognition of
facial expressions and more trust in conspecifics, except
when they are labeled as out-group members, in which case
trust may even decrease after oxytocin administration (De
Dreu et al., 2010; but see Chen et al., 2011). We will explore
the moderating influence of the following design features on
the outcomes of the oxytocin experiments: within-subject
versus between-subject design; the use of a saline placebo or
a placebo with all ingredients of the oxytocin spray except for
the neuropeptide; time delay between oxytocin administra-
tion and test of effect; gender of the participants, and their
awareness of the experimental manipulation.
1. Method
For our meta-analysis we systematically searched the data-
base Web of Science with the key words oxytocin, intranasal*,
and administ* in the title or abstract (the asterisk indicating
that the search contained the word or word fragment). We
excluded intravenous administration studies, studies on the
effects of oxytocin on parturition or breastfeeding (see for a
meta-analysis Wei et al., 2009) non-experimental investiga-
tions of oxytocin, and studies on clinical samples (such as
individuals with autism spectrum disorder, e.g., Hollander
et al., 2007). We finished the search on January 1, 2011. We
identified 23 original empirical papers with 31 pertinent
effect sizes, providing data for three meta-analyses on
effects of oxytocin on face recognition (13 effect sizes,
N = 408), in-group trust (8 effect sizes, N = 317), and out-
group trust (10 effect sizes; N = 505).
The Comprehensive Meta-Analysis (CMA; Borenstein
et al., 2005) program was used to transform the results of
the individual studies into the common metric of Cohen’s d,
or the standardized difference between the intervention and
the control condition. Studies could contribute to all three
meta-analyses but the same subject was never used twice in
the same meta-analysis. The implication however was that
some participants were included in two or more meta-ana-
lyses; which made it impossible to directly compare effect
sizes across the three sets (i.e., effects on face recognition
compared to in-group or out-group trust). Therefore the 85%
confidence intervals for the point estimates of the combined
effect sizes were computed: non-overlapping 85% CI’s sug-
gest a significant difference between combined effect sizes
that are not independent (Goldstein and Healy, 1995; Van
IJzendoorn et al., 2005).Effect sizes in a set of studies may show smaller or larger
variation, and the average or combined effect size across the
studies might capture its central tendency more or less
adequately. Heterogeneity across studies was assessed using
the Q-statistic. Significance tests of combined effect sizes as
well as categorical moderator effects were performed with
the Q-statistic on the basis of a random effects model
(Borenstein et al., 2005). Meta-regression was used to exam-
ine the effect of the delay in minutes between oxytocin
administration and the test of a behavioral effect on the
outcomes of the studies as this was a continuous moderator
(Borenstein et al., 2005).
Studies with a small number of subjects and small effect
sizes may have a lower chance to be published (publication
bias), which might lead to an overestimation of the combined
effect size. We used the ‘‘trim and fill’’ method that esti-
mates the number and effect sizes of the potentially non-
published studies (Duval and Tweedie, 2000a,b) to calculate
the effect of potential data censoring or publication bias on
the outcome of the meta-analyses (Sutton et al., 2000). We
also computed the fail-safe number of studies needed to
reduce a significant combined effect size to non-significance
and compared it to Rosenthal’s (1991) fail-safe number, 5
k + 10 (k = number of studies included). The fail-safe number
is the lowest number of studies with null effects needed to
reduce the combined effect size found in the current meta-
analysis to non-significance. Moreover, we computed the
combined effect size for awareness of condition, i.e.,
whether the subjects knew if they were administered oxy-
tocin or placebo, as reported in part of the studies.
2. Results
The combined effect size for face recognition amounted to
d = 0.21 ( p < .01, 95% CI 0.07, 0.36), in a homogeneous set of
studies (Q [df = 12] = 10.68). Trim-and-fill did not show a
publication bias. Only 19 studies with null effect would be
needed to bring the combined effect size down to a non-
significant level, a considerably smaller number than
Rosenthal’s fail-safe criterion. Although the studies with a
between-subjects design showed the significant and largest
combined effect size (d = 0.30, p = .01), the difference with
the combined outcome of the within-subjects experiments
(d = 0.16, p = .10) was non-significant (Qcontrast = 0.84,
p = .36). The other moderator contrasts could not be com-
puted due to too small sets of studies (see Table 1). Time
delay between oxytocin administration and behavioral test
was not a significant moderator, z = 0.43, p = .67.
The combined effect size for the in-group trust experi-
ments was d = 0.48 ( p < .01, CI 0.19, 0.77) in a heteroge-
neous set of studies (Q [df = 7] = 15.09, p < .05). Trim-and-
fill analysis showed a publication bias, and correcting for 1
missing study outcome the combined effect size amounted to
d = .40 ( p < .05, CI 0.10, 0.70). Forty-four studies with null
effects would be needed to bring the combined effect size
down to a non-significant level, still smaller than Rosenthal’s
fail-safe criterion. Again the six studies with a between-
subjects design showed the largest combined effect size
(d = 0.63, p < .001), but the significance of the difference
with the outcome of the within-subjects experiments
(d = 0.12, p = .53) could not be tested because only two
Table 1 Effects of oxytocin administration on face recognition, trust to in-group, and trust to out-group.
k N d Confidence intervala 95% Homogeneity Q
Face recognition
Total set 13 408 0.21 ** 0.07 to 0.36 10.68
Design
Between-subject 7 276 0.30 * 0.06 to 0.53 7.54
Within-subject 6 132 0.16 0.03 to 0.34 2.30
Gender
Males 10 306 0.23 ** 0.06 to 0.40 9.88
Females 1 16 0.09 0.40 to 0.58
Mixed 2 86 0.17 0.26 to 0.60 0.47
Placebo
Saline 3 113 0.14 0.15 to 0.42 0.53
OT- 8 243 0.19 * 0.01 to 0.37 5.47
Not reported 2 52 0.57 * 0.10 to 1.04 2.16
Trust to in-group
Total set 8 317 0.48 ** 0.19 to 0.77 15.09 *
Design
Between-subject 6 273 0.63 ** 0.35 to 0.92 6.78
Within-subject 2 44 0.12 0.26 to 0.51 1.40
Gender
Males 7 280 0.44 ** 0.14 to 0.75 13.70 *
Females
Mixed 1 37 0.81 0.13 to 1.49
Placebo
Saline 1 17 0.34 0.15 to 0.83
OT 6 263 0.49 * 0.11 to 0.86 14.26 *
Not reported 1 37 0.73 * 0.01 to 1.46
Trust to out-group
Total set 10 505 0.21 0.06 to 0.48 26.70 **
Design
Between-subject 8 431 0.24 0.10 to 0.57 14.67 *
Within-subject 2 74 0.14 0.42 to 0.71 9.48 **
Gender
Males 7 316 0.24 0.12 to 0.60 15.97 *
Females
Mixed 3 189 0.16 0.31 to 0.64 9.36 **
Placebo
Saline 1 18 0.66 * 0.15 to 1.17
OT- 7 408 0.17 0.15 to 0.50 12.01
Not reported 2 79 0.08 0.48 to 0.65 6.15 *
a Based on random effect model unless k = 1.
* p < .05.
** p < .01.
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Time delay between oxytocin administration and behavioral
test was not a significant moderator, z = 1.93, p = .053.
The combined effect size for the out-group trust experi-
ments was not significant, d = 0.21 ( p > .05, CI 0.06, 0.48) in
a heterogeneous set of studies (Q [df = 9] = 26.70, p < .01).
Trim-and-fill indicated a publication bias: two studies needed
to be trimmed and filled, resulting in an adjusted combined
effect size of only d = 0.10 (CI 0.15, 0.36). Studies with a
between-subjects design showed the largest but still non-
significant combined effect size (d = 0.24, p = .16). Time delay
between oxytocin administration and test of an effect was not
a significant moderator, z = 0.47, p = .64.
Fig. 1 shows the combined effect sizes of the three meta-
analyses, with the largest effect sizes for face recognitionand in-group trust. From Fig. 1 (showing 85% confidence
intervals) it may be derived that the three combined effects
were not significantly different, so it cannot be concluded
that effects for in-group trust were significantly stronger
than effects for out-group trust or face recognition.
In a separate meta-analysis, the awareness tests of seven
studies (Alvares et al., 2010; Bartz et al., 2010; Bruins et al.,
1992; Fischer-Shofty et al., 2010; Kirsch et al., 2005; Rim-
mele et al., 2009; Theodoridou et al., 2009) were combined.
The combined Odds ratio for the chance that participants
would correctly guess the type of administration was 0.91
( p = .067, total N = 265). Type of placebo (saline versus
carrier minus the neuropeptide) did not moderate the
awareness outcomes, but the majority (5 out of 7) of the
experiments used the carrier minus oxytocin. Design
Figure 1 Effects of oxytocin administration on face recognition, trust to in-group, and trust to out-group: combined effect sizes (d)
and 85% confidence intervals.
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difference either (Qcontrast = 0.04, p = .84). It should be
noted that in some of the experiments awareness was even
negative, that is, more participants guessed that they were
administered oxytocin when they were not than chance
would allow for (e.g., Theodoridou et al., 2009), showing
that it seems rather difficult for participants to know
whether they received oxytocin or placebo.
3. Discussion and conclusions
Intranasal oxytocin administration enhances the recognition
of facial expressions of emotions, and it elevates the level of
in-group trust. The oxytocin experiments conducted to date
do however not support the hypothesis that out-group trust is
significantly decreased in the oxytocin condition. Intranasal
oxytocin administration indeed seems ‘a sniff of trust’, but
the effect sizes are more modest than popular press has
suggested. Cohen’s d ranged from weak (d = 0.21, face recog-
nition) to moderate (d = 0.43, in-group trust) according to
conventional effect size criteria (Lipsey and Wilson, 2000).
Because the fail-safe numbers are rather small compared
to the number of studies conducted thus far this area of
investigation is not yet saturated. There is an urgent need for
replication and extension of the current set of studies, in
particular of those studies that differentiate between trust
to in-group and trust to out-group members. In the current
meta-analysis the number of participants involved in studies
on out-group trust was largest and thus the likelihood to find a
(negative) effect would be largest in this set of studies.
However, the combined effect size of the out-group trust
experiments was not significantly different from zero
whereas that of the in-group experiments was substantial.
The current meta-analysis is also limited because of the
limited room for moderator analyses as a consequence of the
small set of effect sizes in each of the moderator subsets. A
robust test of the moderating role of design features such as
gender, kind of placebo, and participants’ awareness of the
oxytocin administration was impossible. In the overwhelmingmajority of studies a dose of 24 IU of oxytocin was used, and a
delay of 35—50 min between administration and observation
was planned. We therefore do not know whether lower or
higher doses of oxytocin have similar effects, and it is unclear
how much time outside the 35—50 min window it takes before
the oxytocin effects emerge and fade out.
Nevertheless, the use of intranasal oxytocin in experi-
ments on emotion recognition and trust has led to a promising
and grounded hypothesis, namely that intranasally adminis-
tered oxytocin can change emotion perception and behavior
in trusting relationships. This first wave of experiments
documents a proof of principle of the perceptual and beha-
vioral effects of intranasal administration of an important
neuropeptide involved in social-emotional relationships. It
opens a myriad of possibilities to uncover the development
and dynamics of emotional empathy and trust in close rela-
tionships.
One of the most exciting but unexplored areas for future
studies is the effect of oxytocin administration on the impact
of cognitive or behavioral interventions targeting at the
improvement of parent—child or partner relationships. Cog-
nitive behavior therapy of marital problems (Ost, 2008) and
interaction-focused parent training (Stein et al., 2006) might
become more effective if oxytocin administration would be a
component of the treatment and used to sharpen the percep-
tion of emotions in partner or child. Oxytocin may lower the
level of resistance against dealing constructively with nega-
tive emotional signals of partner or child (Riem et al., 2011).
Oxytocin might not be the equivalent of trust and it might
not be a stand-alone treatment drug for interpersonal pro-
blems but it may prove to be an important catalyst in broader
relationship therapies and interventions.
Role of the funding sources
The Netherlands Organization for Scientific Research had no
further role in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.
442 M.H. Van IJzendoorn, M.J. Bakermans-KranenburgConflict of interest
The authors declare that they have no conflicts of interest.
Acknowledgments
MJBK and MHvIJ were supported by awards from the Nether-
lands Organization for Scientific Research (MJBK: VICI grant
no. 453-09-003; MHvIJ: SPINOZA prize).
References*
*Alvares, G.A., Hickie, I.B., Guastella, A.J., 2010. Acute effects of
intranasal oxytocin on subjective and behavioral responses to
social rejection. Experimental and Clinical Psychopharmacology
18, 316—321, doi:10.1037/a0019719.
*Bartz, J.A., Zaki, J., Bolger, N., Hollander, E., Ludwig, N.N., Kolev-
zon, A., et al., 2010. Oxytocin selectively improves empathic
accuracy. Psychological Science 21, 1426—1428, doi:10.1177/
0956797610383439.
*Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U.,
Fehr, E., 2008. Oxytocin shapes the neural circuitry of trust and
trust adaptation in humans. Neuron 58, 639—650, doi:10.1016/
j.neuron.2008.04.009.
Borenstein, M., Rothstein, D., Cohen, J., 2005. Comprehensive Meta-
analysis: A Computer Program for Research Synthesis [including
computer software]. Biostat, Englewood, NJ.
*Bruins, J., Hijman, R., Van Ree, J.M., 1992. Effect of a single dose of
des-glycinamide-[arg8]vasopressin or oxytocin on cognitive-pro-
cesses in young healthy-subjects. Peptides 13, 461—468,
doi:10.1016/0196-9781(92)90075-E.
Buchheim, A., Heinrichs, M., George, C., Pokorny, D., Koops, E.,
Henningsen, P., O’Connor, M.F., Gundel, H., 2009. Oxytocin
enhances the experience of attachment security. Psychoneuroen-
docrinology 34, 1417—1422, doi:10.1016/j.psyneuen.2009.04.002.
Carter, C.S., 1998. Neuroendocrine perspectives on social attach-
ment and love. Psychoneuroendocrinology 23, 779—818,
doi:10.1016/S0306-4530(98)00055-9.
Chen, F.S., Kumsta, R., Heinrichs, M., 2011. Oxytocin and intergroup
relations: goodwill is not a fixed pie. Proceedings of the National
Academy of Sciences of the United States of America 108, E45,
doi:10.1073/pnas.1101633108.
*De Dreu, C.K.W., Greer, L.L., Handgraaf, M.J.J., Shalvi, S., Van
Kleef, G.A., Baas, M., et al., 2010. The neuropeptide oxytocin
regulates parochial altruism in intergroup conflict among
humans. Science 328, 1408—1411, doi:10.1126/science.1189047.
*Di Simplicio, M., Massey-Chase, R., Cowen, P.J., Harmer, C.J.,
2009. Oxytocin enhances processing of positive versus negative
emotional information in healthy male volunteers. Journal of
Psychopharmacology 23, 241—248, doi:10.1177/026988110
8095705.
*Domes, G., Heinrichs, M., Michel, A., Berger, C., Herpertz, S.C.,
2007. Oxytocin improves ‘‘mind-reading’’ in humans. Biological
Psychiatry 61, 731—733, doi:10.1016/j.biopsych.2006.07.015.
*Domes, G., Lischke, A., Berger, C., Grossmann, A., Hauenstein, K.,
Heinrichs, M., Herpertz, S.C., 2010. Effects of intranasal oxytocin
on emotional face processing in women. Psychoneuroendocrinol-
ogy 35, 83—93, doi:10.1016/j.psyneuen.2009.06.016.
Duval, S., Tweedie, R., 2000a. A nonparametric ‘‘trim and fill’’
method for accounting for publication bias in meta-analysis.
Journal of the American Statistical Association 95, 89—98.* Studies included in the meta-analysis.Duval, S., Tweedie, R., 2000b. Trim and fill: a simple funnel-plot-
based method of testing and adjusting for publication bias in
meta-analysis. Biometrics 56, 455—463.
Ebstein, R.P., Israel, S., Lerer, E., Uzefovsky, F., Shalev, I., Gritsenko,
I., Riebold, M., Salomon, S., Yirmiya, A., 2009. Arginine vaso-
pressin and oxytocin modulate human social behavior. Annals of
the New York Academy of Sciences 1167, 87—102, doi:10.1111/
j.1749-6632.2009.04541.x.
Eisenegger, C., Naef, M., Snozzi, R., Heinrichs, M., Fehr, E., 2010.
Prejudice and truth about the effect of testosterone on human
bargaining behaviour. Nature 463, 356—360, doi:10.1038/na-
ture08711.
Feldman, R., Gordon, I., Schneiderman, I., Weissman, O., 2010.
Natural variations in maternal and paternal care are associated
with systematic changes in oxytocin following parent—infant con-
tact. Psychoneuroendocrinology 35, 1133—1141, doi:10.1016/
j.psyneuen.2010.01.013.
Feldman, R., Weller, A., Zagoori-Sharon, O., Levine, A., 2007. Evi-
dence for a neuroendrocrinological foundation of human affilia-
tion. Psychological Science 18, 965—970, doi:10.1111/j.1467-
9280.2007.02010.x.
*Fischer-Shofty, M., Shamay-Tsoory, S.G., Harari, H., Levkovitz, Y.,
2010. The effect of intranasal administration of oxytocin on fear
recognition. Neuropsychologia 48, 179—184, doi:10.1016/j.neu-
ropsychologia.2009.09.003.
Galbally, M., Lewis, A., Van IJzendoorn, M.H., Permezel, M., 2011.
The role of oxytocin in maternal—infant relationships: a system-
atic review of human studies. Harvard Review of Psychiatry 19, 1—
14, doi:10.3109/10673229.2011.549771.
*Gamer, M., Zurowski, B., Buchel, C., 2010. Different amygdala
subregions mediate valence-related and attentional effects of
oxytocin in humans. Proceedings of the National Academy of
Sciences of the United States of America 107, 9400—9405,
doi:10.1073/pnas.1000985107.
Goldstein, H., Healy, M.J.R., 1995. The graphical presentation of a
collection of means. Journal of the Royal Statistical Society,
Series A 158, 175—177.
*Heinrichs, M., Baumgartner, T., Kirschbaum, C., Ehlert, U., 2003.
Social support and oxytocin interact to suppress cortisol and
subjective responses to psychological stress. Biological Psychi-
atry 54, 1389—1398, doi:10.1016/S0006-3223(03)00465-7.
Heinrichs, M., Domes, G., 2008. Neuropeptides and social behavior:
effects of oxytocin and vasopressin in humans. Progress in
Brain Research 170, 337—350, doi:10.1016/S0079-6123(08)
00428-7.
Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya,
L., et al., 2007. Oxytocin increases retention of social cognition
in autism. Biological Psychiatry 61, 498—503, doi:10.1016/j.biop-
sych.2006.05.030.
*Hurlemann, R., Patin, A., Onur, O.A., Cohen, M.X., Baumgarter, T.,
Metzler, S., et al., 2010. Oxytocin enhances amygdala-depen-
dent, socially reinforced learning and emotional empathy in
humans. Journal of Neuroscience 30, 4999—5007, doi:10.1523/
JNEUROSCI5538-09.2010.
Insel, T.R., 1992. Oxytocin — a neuropeptide for affiliation: evidence
from behavioral, receptor autoradiographic, and comparative
studies. Psychoneuroendocrinology 17, 3—35, doi:10.1016/
0306-4530(92)90073-G.
Insel, T.R., 2010. The challenge of translation in social neuroscience:
a review of oxytocin, vasopressin, and affiliative behavior. Neuron
65, 768—779 101016/j.neuron.2010.03. 005.
*Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S.,
et al., 2005. Oxytocin modulates neural circuitry for social
cognition and fear in humans. Journal of Neuroscience 25,
11489—11493, doi:10.1523/JNEUROSCI3984-05.2005.
*Kosfeld, M., Heinrichs, M., Zak, P.J., Fischbacher, U., Fehr, E., 2005.
Oxytocin increases trust in humans. Nature 435, 673—676,
doi:10.1038/nature03701.
A sniff of trust 443*Labuschagne, I., Phan, K.L., Wood, A., Angstadt, M., Chua, P.,
Heinrichs, M., Stout, J.C., Nathan, P.J., 2010. Oxytocin attenu-
ates amygdala reactivity to fear in generalized social anxiety
disorder. Neuropsychopharmacology 35, 2403—2413, doi:10.1038
/npp.2010.123.
Lipsey, M.W., Wilson, D.B., 2000. Practical Meta-analysis. Sage,
Thousand Oaks, CA.
MacDonald, K., MacDonald, T.M., 2010. The peptide that binds: a
systematic review of oxytocin and its prosocial effects in humans.
Harvard Review of Psychiatry 18, 1—21, doi:10.3109/1067322
0903523615.
*Marsh, A.A., Yu, H.H., Pine, D.S., Blair, R.J.R., 2010. Oxytocin
improves specific recognition of positive facial expressions. Psy-
chofarmacology 209, 225—232, doi:10.1007/s00213-010-1780-4.
*Naber, F., Van IJzendoorn, M.H., Deschamps, P., Van Engeland, H.,
Bakermans-Kranenburg, M.J., 2010. Intranasal oxytocin increases
fathers’ observed responsiveness during play with their children:
a double-blind within-subject experiment. Psychoneuroendocri-
nology 35, 1583—1586, doi:10.1016/j.psyneuen.2010.04.007.
Ost, L.-G., 2008. Efficacy of the third wave of behavioral therapies: a
systematic review and meta-analysis. Behaviour Research and
Therapy 46, 296—321, doi:10.1016/j.brat.2007.12.005.
Perry, A., Bentin, S., Shalev, I., Israel, S., Uzefovsky, F., Bar-On, D.,
Ebstein, R.P., 2010. Intranasal oxytocin modulates EEG mu/alpha
and beta rhythms during perception of biological motion. Psy-
choneuroendocrinology 35, 1446—1453, doi:10.1016/j.psyneuen.
2010.04.011.
Riem, M.M.E., Bakermans-Kranenburg, M.J., Pieper, S., Tops, M.,
Boksem, M.A.S., Vermeiren, R.R.J.M., Van IJzendoorn, M.H.,
Rombouts, S.A.R.B., 2011. Oxytocin modulates amygdala, insula
and inferior frontal gyrus responses to infant crying: a randomized
control trial. Biological Psychiatry, doi:10.1016/j.biopsych.
2011.02.006.*Rimmele, U., Hediger, K., Heinrichs, M., Klaver, P., 2009. Oxytocin
makes a face in memory familiar. Journal of Neuroscience 29, 38—
42, doi:10.1523/JNEUROSCI4260-08.2009.
Rosenthal, R., 1991. Meta-analytic Procedures for Social Research.
Sage, Newbury Park, CA.
*Savaskan, E., Ehrhardt, R., Schulz, A., Walter, M., Schachinger, H.,
2008. Post-learning intranasal oxytocin modulates human memo-
ry for facial identity. Psychoneuroendocrinology 33, 368—374,
doi:10.1016/j.psyneuen.2007.12.004.
*Shamay-Tsoory, S.G., Fischer, M., Dvash, J., Harari, H., Perach-
Bloom, N., Levkovitz, Y., 2009. Intranasal administration of
oxytocin increases envy and schadenfreude (gloating). Biological
Psychiatry 66, 864—870, doi:10.1016/j.biopsych.2009.06.009.
Stein, A., Woolley, H., Senior, R., Hertzman, L., Lovel, M., Lee, J.,
et al., 2006. Treating disturbances in the relationship between
mothers with bulimic eating disorders and their infants: a ran-
domized controlled trial of video feedback. The American Journal
of Psychiatry 163, 899—906.
Sutton, A.J., Duval, S.J., Tweedie, R.L., Abrams, K.R., Jones, D.R.,
2000. Empirical assessment of effect of publication bias on meta-
analyses. British Medical Journal 320, 1574—1577, doi:10.1136/
bmj.320.7249.1574.
*Theodoridou, A., Rowe, A.C., Penton-Voak, I.S., Rogers, P.J., 2009.
Oxytocin and social perception: oxytocin increases perceived
facial trustworthiness and attractiveness. Hormones and Behavior
56, 128—132, doi:10.1016/j.yhbeh.2009.03.019.
Van IJzendoorn, M.H., Juffer, F., Klein Poelhuis, C.W., 2005. IQ and
school achievement of adopted children: a meta-analytic com-
parison with non-adopted children. Psychological Bulletin 131,
301—316, doi:10.1037/0033-2909.131.2.301.
Wei, S.Q., Luo, Z.C., Xu, H.R., Fraser, W.D., 2009. The effect of early
oxytocin augmentation in labor: a meta-analysis. Obstetrics and
Gynecology 114, 641—649, doi:10.1097/AOG.0b013e3181b11cb8.
